Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Oregovomab

EU orphan designation number: EU/3/02/109   
Active ingredient: Oregovomab
Indication: Treatment of ovarian cancer
Sponsor: ViRexx International Corp. Limited
1 Main Street, Blessington, County Wicklow, Ireland

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
01/08/2002 Centralised Orphan - Designation EMEA/OD/019/02 (2002)3014 of 30/07/2002
25/10/2004 Other procedure
04/05/2007 Centralised Orphan - Transfer of orphan designation EMEA/OD/019/02/T/01 (2007)2008 of 02/05/2007